George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.

The Baloch Liberation Army (BLA) has claimed responsibility for two attacks in Balochistan, killing 29 Pakistani soldiers. In ...

In a major development, the Balochistan Liberation Army (BLA) has launched a deadly attack on Pakistani military forces, ...

Balochistan's security situation took a dramatic turn this week, as both banned separatist groups, Balochistan Liberation ...

Police and government officials in southwestern Pakistan say that gunmen have opened fire on a passenger bus, killing at least three people and wounding seven others ...

The U.S. FDA has accepted a Biologics License Application (BLA) for BAT2506, a proposed biosimilar to Simponi (golimumab).

GSK (GSK) stock in focus as the FDA staff raise safety concerns over Blenrep combo for multiple myeloma ahead of an AdCom ...

Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA ...

Nanoscope Therapeutics submitted the first modules of a biologics license application for MCO-010, an investigational gene ...

Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain ...